{"id":"NCT02097745","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies","officialTitle":"An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2014-03-27","resultsPosted":"2014-11-07","lastUpdate":"2016-11-03"},"enrollment":341,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":["MabThera/Rituxan"]}],"arms":[{"label":"MabThera/Rituxan","type":"EXPERIMENTAL"}],"summary":"This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response","timeFrame":"Baseline to the end of the retreatment period (up to 7 years, 6 months)","effectByArm":[{"arm":"Rituximab","deltaMin":67.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":97,"countries":["United States","Belgium","Canada","France","Germany","Ireland","Israel","Italy","Netherlands","Norway","United Kingdom"]},"refs":{"pmids":["18050221"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":140},"commonTop":["Rheumatoid arthritis","Infusion related reaction","Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection"]}}